JP2012508017A - 抗ｄｌｌ４抗体及びその使用 - Google Patents
抗ｄｌｌ４抗体及びその使用 Download PDFInfo
- Publication number
- JP2012508017A JP2012508017A JP2011535651A JP2011535651A JP2012508017A JP 2012508017 A JP2012508017 A JP 2012508017A JP 2011535651 A JP2011535651 A JP 2011535651A JP 2011535651 A JP2011535651 A JP 2011535651A JP 2012508017 A JP2012508017 A JP 2012508017A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- chain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims abstract description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 44
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 11
- 102100033553 Delta-like protein 4 Human genes 0.000 claims abstract 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 379
- 230000027455 binding Effects 0.000 claims description 172
- 238000009739 binding Methods 0.000 claims description 169
- 150000001413 amino acids Chemical class 0.000 claims description 168
- 238000006467 substitution reaction Methods 0.000 claims description 166
- 108090000623 proteins and genes Proteins 0.000 claims description 151
- 210000004602 germ cell Anatomy 0.000 claims description 144
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 110
- 239000000427 antigen Substances 0.000 claims description 102
- 108091007433 antigens Proteins 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 100
- 210000004027 cell Anatomy 0.000 claims description 98
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 98
- 125000003729 nucleotide group Chemical group 0.000 claims description 89
- 229920001184 polypeptide Polymers 0.000 claims description 88
- 239000012634 fragment Substances 0.000 claims description 84
- 239000002773 nucleotide Substances 0.000 claims description 83
- 230000000694 effects Effects 0.000 claims description 74
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 69
- 101000839682 Homo sapiens Immunoglobulin heavy variable 4-34 Proteins 0.000 claims description 45
- 102100028306 Immunoglobulin heavy variable 4-34 Human genes 0.000 claims description 45
- 230000004048 modification Effects 0.000 claims description 39
- 238000012986 modification Methods 0.000 claims description 39
- 102000005650 Notch Receptors Human genes 0.000 claims description 31
- 108010070047 Notch Receptors Proteins 0.000 claims description 31
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 claims description 30
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 102220353972 c.292T>G Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 26
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 25
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 230000001850 reproductive effect Effects 0.000 claims description 25
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 claims description 24
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 claims description 24
- 102220587343 Cellular tumor antigen p53_S99P_mutation Human genes 0.000 claims description 23
- 102100026296 Protein S100-A16 Human genes 0.000 claims description 23
- 102220228928 rs1064793060 Human genes 0.000 claims description 22
- 102220040126 rs371657037 Human genes 0.000 claims description 22
- 102220554706 Holliday junction recognition protein_S30T_mutation Human genes 0.000 claims description 20
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims description 20
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- -1 S100H Proteins 0.000 claims description 18
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims description 17
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims description 17
- 102220046035 rs587782586 Human genes 0.000 claims description 17
- 102220123567 rs886043442 Human genes 0.000 claims description 17
- 108700028369 Alleles Proteins 0.000 claims description 16
- 102220590441 Epoxide hydrolase 3_S30D_mutation Human genes 0.000 claims description 16
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims description 16
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 claims description 16
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims description 16
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 102200006408 rs746834149 Human genes 0.000 claims description 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 15
- 102000044457 human DLL4 Human genes 0.000 claims description 15
- 102220043120 rs144094344 Human genes 0.000 claims description 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 14
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 14
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 13
- 102220562905 Bromodomain-containing protein 1_I51K_mutation Human genes 0.000 claims description 12
- 102220597389 G0/G1 switch protein 2_R54A_mutation Human genes 0.000 claims description 12
- 102220497573 Leukotriene B4 receptor 1_N52A_mutation Human genes 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102220265335 rs139105272 Human genes 0.000 claims description 12
- 102220601218 Microtubule-associated protein tau_T30A_mutation Human genes 0.000 claims description 11
- 102220534415 Tyrosine-protein phosphatase non-receptor type 1_S50D_mutation Human genes 0.000 claims description 11
- 102200094314 rs74315399 Human genes 0.000 claims description 11
- 101000978126 Homo sapiens Immunoglobulin lambda variable 8-61 Proteins 0.000 claims description 10
- 102100023752 Immunoglobulin lambda variable 8-61 Human genes 0.000 claims description 10
- 102220580970 Induced myeloid leukemia cell differentiation protein Mcl-1_I50T_mutation Human genes 0.000 claims description 10
- 102220613568 Potassium voltage-gated channel subfamily H member 2_F29A_mutation Human genes 0.000 claims description 10
- 102220509115 Sphingosine 1-phosphate receptor 1_Y97V_mutation Human genes 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 102200075235 rs118204106 Human genes 0.000 claims description 10
- 102220012182 rs373164247 Human genes 0.000 claims description 10
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 claims description 9
- 102220522291 THAP domain-containing protein 1_S31A_mutation Human genes 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 102220276093 rs1555932427 Human genes 0.000 claims description 9
- 102220239639 rs758681737 Human genes 0.000 claims description 9
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 claims description 8
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims description 8
- 101000989060 Homo sapiens Immunoglobulin heavy variable 6-1 Proteins 0.000 claims description 8
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 claims description 8
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 claims description 8
- 102220511640 Immunoglobulin heavy joining 1_S30L_mutation Human genes 0.000 claims description 8
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims description 8
- 102100029416 Immunoglobulin heavy variable 6-1 Human genes 0.000 claims description 8
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 claims description 8
- 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 claims description 8
- 102220503895 Meiotic recombination protein REC8 homolog_S92V_mutation Human genes 0.000 claims description 8
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 claims description 8
- 102220532163 WW domain-binding protein 11_I51S_mutation Human genes 0.000 claims description 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 8
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 102200110749 rs28941476 Human genes 0.000 claims description 8
- 102220045199 rs587781908 Human genes 0.000 claims description 8
- 102220224491 rs765799649 Human genes 0.000 claims description 8
- 102220097978 rs780920036 Human genes 0.000 claims description 8
- 102220625606 Ankyrin repeat domain-containing protein 2_S94G_mutation Human genes 0.000 claims description 7
- 102220566212 Cyclic AMP-dependent transcription factor ATF-7_T51A_mutation Human genes 0.000 claims description 7
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims description 7
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 claims description 7
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims description 7
- 102220642036 Lipoma-preferred partner_S76N_mutation Human genes 0.000 claims description 7
- 102220637445 Mitochondrial genome maintenance exonuclease 1_M92A_mutation Human genes 0.000 claims description 7
- 102220537350 Neural retina-specific leucine zipper protein_S50L_mutation Human genes 0.000 claims description 7
- 102220471545 Single-stranded DNA cytosine deaminase_S26A_mutation Human genes 0.000 claims description 7
- 102220471558 Single-stranded DNA cytosine deaminase_S94A_mutation Human genes 0.000 claims description 7
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 102220230165 rs1064793071 Human genes 0.000 claims description 7
- 102220003317 rs137852699 Human genes 0.000 claims description 7
- 102220011589 rs200960071 Human genes 0.000 claims description 7
- 102220006845 rs281874706 Human genes 0.000 claims description 7
- 102220044474 rs587781329 Human genes 0.000 claims description 7
- 102220337697 rs72555390 Human genes 0.000 claims description 7
- 102200006406 rs746834149 Human genes 0.000 claims description 7
- 102220094066 rs876659747 Human genes 0.000 claims description 7
- 102220554162 APC membrane recruitment protein 1_I34A_mutation Human genes 0.000 claims description 6
- 102220485321 ATP-dependent DNA/RNA helicase DHX36_G55L_mutation Human genes 0.000 claims description 6
- 102220547840 Apoptosis-associated speck-like protein containing a CARD_L25Q_mutation Human genes 0.000 claims description 6
- 102220475086 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6_L90A_mutation Human genes 0.000 claims description 6
- 102220523639 C-C motif chemokine 2_S50Q_mutation Human genes 0.000 claims description 6
- 102220587363 Cellular tumor antigen p53_S94L_mutation Human genes 0.000 claims description 6
- 102220566211 Cyclic AMP-dependent transcription factor ATF-7_T51D_mutation Human genes 0.000 claims description 6
- 102220632031 Decorin_D54A_mutation Human genes 0.000 claims description 6
- 102220632043 Decorin_D56A_mutation Human genes 0.000 claims description 6
- 102220526112 Dihydrofolate reductase_M92F_mutation Human genes 0.000 claims description 6
- 102220526111 Dihydrofolate reductase_M92L_mutation Human genes 0.000 claims description 6
- 102220519145 E3 ubiquitin/ISG15 ligase TRIM25_V89G_mutation Human genes 0.000 claims description 6
- 102220475128 Ectodysplasin-A_W33A_mutation Human genes 0.000 claims description 6
- 102220559985 Epsilon-sarcoglycan_M92T_mutation Human genes 0.000 claims description 6
- 102220588493 Hemoglobin subunit beta_T51K_mutation Human genes 0.000 claims description 6
- 102220483804 High mobility group protein B1_Y97H_mutation Human genes 0.000 claims description 6
- 102220478979 Interleukin-4 receptor subunit alpha_Y99A_mutation Human genes 0.000 claims description 6
- 102220465274 Purine nucleoside phosphorylase LACC1_Y52A_mutation Human genes 0.000 claims description 6
- 102220612295 Putative coiled-coil domain-containing protein 144 N-terminal-like_S55D_mutation Human genes 0.000 claims description 6
- 102220573220 Ras-related protein Ral-A_S50W_mutation Human genes 0.000 claims description 6
- 102220509670 SAM and SH3 domain-containing protein 1_Y31A_mutation Human genes 0.000 claims description 6
- 102220536914 Transcription factor JunD_P33A_mutation Human genes 0.000 claims description 6
- 102220474577 Ubiquitin-conjugating enzyme E2 D1_S94E_mutation Human genes 0.000 claims description 6
- 102220594970 Vasopressin-neurophysin 2-copeptin_T51N_mutation Human genes 0.000 claims description 6
- 102220514520 Vitronectin_T76E_mutation Human genes 0.000 claims description 6
- 102220546632 Voltage-dependent L-type calcium channel subunit beta-2_S55N_mutation Human genes 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 102200016928 c.100G>A Human genes 0.000 claims description 6
- 102220361905 c.148A>C Human genes 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 102200006655 rs104894230 Human genes 0.000 claims description 6
- 102200041211 rs104894459 Human genes 0.000 claims description 6
- 102220209728 rs1057523598 Human genes 0.000 claims description 6
- 102220216591 rs1060503509 Human genes 0.000 claims description 6
- 102220187877 rs143008696 Human genes 0.000 claims description 6
- 102220328414 rs1453134737 Human genes 0.000 claims description 6
- 102200079914 rs193302884 Human genes 0.000 claims description 6
- 102220011222 rs281865133 Human genes 0.000 claims description 6
- 102200043447 rs281875243 Human genes 0.000 claims description 6
- 102200043446 rs281875252 Human genes 0.000 claims description 6
- 102200082820 rs33960931 Human genes 0.000 claims description 6
- 102220005308 rs33960931 Human genes 0.000 claims description 6
- 102220020162 rs397508045 Human genes 0.000 claims description 6
- 102220015169 rs397517383 Human genes 0.000 claims description 6
- 102220094065 rs587782586 Human genes 0.000 claims description 6
- 102200030476 rs615942 Human genes 0.000 claims description 6
- 102220169097 rs61730848 Human genes 0.000 claims description 6
- 102220289621 rs63750336 Human genes 0.000 claims description 6
- 102200101937 rs72554349 Human genes 0.000 claims description 6
- 102220094747 rs770566177 Human genes 0.000 claims description 6
- 102220234886 rs778952116 Human genes 0.000 claims description 6
- 102220068510 rs794727508 Human genes 0.000 claims description 6
- 102200153318 rs913934445 Human genes 0.000 claims description 6
- 102220496020 5-hydroxytryptamine receptor 3B_N52S_mutation Human genes 0.000 claims description 5
- 102220497137 5-hydroxytryptamine receptor 3B_S30G_mutation Human genes 0.000 claims description 5
- 102220511774 Adenylosuccinate lyase_S31N_mutation Human genes 0.000 claims description 5
- 102220479279 Anoctamin-3_N52T_mutation Human genes 0.000 claims description 5
- 102220573534 C-C motif chemokine 5_G55K_mutation Human genes 0.000 claims description 5
- 102220632024 Decorin_N53A_mutation Human genes 0.000 claims description 5
- 102220619583 Glycine receptor subunit alpha-1_G55V_mutation Human genes 0.000 claims description 5
- 102220543692 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas_N53G_mutation Human genes 0.000 claims description 5
- 102220537095 Hemoglobin subunit epsilon_N53H_mutation Human genes 0.000 claims description 5
- 102220491788 High mobility group protein B1_S53E_mutation Human genes 0.000 claims description 5
- 102220471962 Histone deacetylase 7_S55W_mutation Human genes 0.000 claims description 5
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 claims description 5
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims description 5
- 101000978120 Homo sapiens Probable non-functional immunoglobulin lambda variable 11-55 Proteins 0.000 claims description 5
- 101001005499 Homo sapiens Probable non-functional immunoglobulin lambda variable 5-48 Proteins 0.000 claims description 5
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 claims description 5
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims description 5
- 102220631528 Krueppel-like factor 13_G55W_mutation Human genes 0.000 claims description 5
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims description 5
- 102220537824 Nebulette_S99A_mutation Human genes 0.000 claims description 5
- 102220592550 Neuroserpin_S52R_mutation Human genes 0.000 claims description 5
- 102220502536 Platelet-activating factor acetylhydrolase IB subunit alpha2_G55E_mutation Human genes 0.000 claims description 5
- 102220559090 Potassium voltage-gated channel subfamily E member 1_S28T_mutation Human genes 0.000 claims description 5
- 102100023451 Probable non-functional immunoglobulin lambda variable 11-55 Human genes 0.000 claims description 5
- 102100025167 Probable non-functional immunoglobulin lambda variable 5-48 Human genes 0.000 claims description 5
- 102220467908 Protein Dok-7_S30W_mutation Human genes 0.000 claims description 5
- 102100023097 Protein S100-A1 Human genes 0.000 claims description 5
- 102100021486 Protein S100-G Human genes 0.000 claims description 5
- 102220615003 RELT-like protein 2_G100L_mutation Human genes 0.000 claims description 5
- 101100226846 Strongylocentrotus purpuratus EGF3 gene Proteins 0.000 claims description 5
- 102220578494 Suppressor of fused homolog_R95A_mutation Human genes 0.000 claims description 5
- 102220536512 THAP domain-containing protein 1_S52A_mutation Human genes 0.000 claims description 5
- 102220524532 Tumor necrosis factor receptor superfamily member 19_S31T_mutation Human genes 0.000 claims description 5
- 102220559219 Voltage-dependent L-type calcium channel subunit alpha-1C_S30R_mutation Human genes 0.000 claims description 5
- 102220353096 c.163G>C Human genes 0.000 claims description 5
- 102220358598 c.296C>G Human genes 0.000 claims description 5
- 102220346421 c.92C>A Human genes 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 102220028823 rs115928999 Human genes 0.000 claims description 5
- 102200148733 rs116840794 Human genes 0.000 claims description 5
- 102220318984 rs150326789 Human genes 0.000 claims description 5
- 102220320206 rs1554431444 Human genes 0.000 claims description 5
- 102200048328 rs1801270 Human genes 0.000 claims description 5
- 102200097284 rs199472834 Human genes 0.000 claims description 5
- 102200133096 rs199473644 Human genes 0.000 claims description 5
- 102200082871 rs35802118 Human genes 0.000 claims description 5
- 102200123491 rs72555390 Human genes 0.000 claims description 5
- 102220121884 rs768260007 Human genes 0.000 claims description 5
- 102220092171 rs770694213 Human genes 0.000 claims description 5
- 102220328494 rs78028658 Human genes 0.000 claims description 5
- 102220087056 rs864622464 Human genes 0.000 claims description 5
- 102220172123 rs886048669 Human genes 0.000 claims description 5
- 102220497105 5-hydroxytryptamine receptor 3B_T56A_mutation Human genes 0.000 claims description 4
- 102220617612 B-cell acute lymphoblastic leukemia-expressed protein_N93H_mutation Human genes 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102220518361 Casein kinase I isoform gamma-2_Y33A_mutation Human genes 0.000 claims description 4
- 102100032759 Cysteine-rich motor neuron 1 protein Human genes 0.000 claims description 4
- 102220569940 Cytochrome P450 1B1_S28W_mutation Human genes 0.000 claims description 4
- 102220510722 Dual specificity tyrosine-phosphorylation-regulated kinase 2_S98G_mutation Human genes 0.000 claims description 4
- 102220607093 Gap junction beta-1 protein_S52P_mutation Human genes 0.000 claims description 4
- 102220612416 Mitogen-activated protein kinase kinase kinase 1_S92N_mutation Human genes 0.000 claims description 4
- 102220631334 NCK-interacting protein with SH3 domain_S92G_mutation Human genes 0.000 claims description 4
- 102220572954 Netrin receptor UNC5C_S28F_mutation Human genes 0.000 claims description 4
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 claims description 4
- 102100029811 Protein S100-A11 Human genes 0.000 claims description 4
- 102220519841 Putative neutrophil cytosol factor 1B_S30P_mutation Human genes 0.000 claims description 4
- 102220596972 Ski oncogene_S31L_mutation Human genes 0.000 claims description 4
- 102220606007 Sorting nexin-10_Y32S_mutation Human genes 0.000 claims description 4
- 102220504159 Testis-specific XK-related protein, Y-linked 2_N93Q_mutation Human genes 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 102220437982 c.160G>T Human genes 0.000 claims description 4
- 102220290142 c.186C>A Human genes 0.000 claims description 4
- 102220349282 c.275C>G Human genes 0.000 claims description 4
- 102200107976 c.296C>T Human genes 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 208000037765 diseases and disorders Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 102200103823 rs104886043 Human genes 0.000 claims description 4
- 102200046706 rs104893869 Human genes 0.000 claims description 4
- 102200076230 rs104894127 Human genes 0.000 claims description 4
- 102200142367 rs104894554 Human genes 0.000 claims description 4
- 102220196624 rs1057518977 Human genes 0.000 claims description 4
- 102220218621 rs1060501106 Human genes 0.000 claims description 4
- 102220233028 rs1085307691 Human genes 0.000 claims description 4
- 102200118914 rs120074145 Human genes 0.000 claims description 4
- 102200058924 rs121909542 Human genes 0.000 claims description 4
- 102200115358 rs121918322 Human genes 0.000 claims description 4
- 102220036452 rs137882485 Human genes 0.000 claims description 4
- 102220191772 rs149875299 Human genes 0.000 claims description 4
- 102200061168 rs150338273 Human genes 0.000 claims description 4
- 102220242992 rs1553178041 Human genes 0.000 claims description 4
- 102220317885 rs1554069716 Human genes 0.000 claims description 4
- 102220287941 rs1555932714 Human genes 0.000 claims description 4
- 102200133063 rs199473350 Human genes 0.000 claims description 4
- 102220084157 rs370502517 Human genes 0.000 claims description 4
- 102220016203 rs397507622 Human genes 0.000 claims description 4
- 102220139130 rs570799464 Human genes 0.000 claims description 4
- 102200114146 rs61748123 Human genes 0.000 claims description 4
- 102200001738 rs72552724 Human genes 0.000 claims description 4
- 102220058298 rs730881402 Human genes 0.000 claims description 4
- 102220218616 rs746322193 Human genes 0.000 claims description 4
- 102220082204 rs753215899 Human genes 0.000 claims description 4
- 102220463950 rs7782939 Human genes 0.000 claims description 4
- 102220328195 rs781611267 Human genes 0.000 claims description 4
- 102220062178 rs786202417 Human genes 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000007792 addition Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 102200046707 rs104893869 Human genes 0.000 claims description 3
- 102200097263 rs199472844 Human genes 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 102220240604 rs373669452 Human genes 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 102200115585 rs539699299 Human genes 0.000 claims 7
- 102220495789 Alkaline ceramidase 1_S28A_mutation Human genes 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 230000003527 anti-angiogenesis Effects 0.000 claims 4
- 102220259666 rs550137245 Human genes 0.000 claims 4
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 3
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 3
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 3
- 102220511662 Heme oxygenase 1_S58A_mutation Human genes 0.000 claims 2
- 102220569743 Programmed cell death protein 6_Y91A_mutation Human genes 0.000 claims 2
- 102220469971 Tryptase delta_Y32A_mutation Human genes 0.000 claims 2
- 102220352372 c.148T>G Human genes 0.000 claims 2
- 102220280629 rs1555085496 Human genes 0.000 claims 2
- 102100035355 Cadherin-related family member 3 Human genes 0.000 claims 1
- 102220511665 Heme oxygenase 1_S76A_mutation Human genes 0.000 claims 1
- 101000737802 Homo sapiens Cadherin-related family member 3 Proteins 0.000 claims 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 claims 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 claims 1
- 102220482828 Mitochondrial coenzyme A diphosphatase NUDT8_E96A_mutation Human genes 0.000 claims 1
- 102220521977 THAP domain-containing protein 1_T28A_mutation Human genes 0.000 claims 1
- 102220469732 Voltage-dependent L-type calcium channel subunit beta-2_S53A_mutation Human genes 0.000 claims 1
- 102220532167 WW domain-binding protein 11_D50S_mutation Human genes 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 102220041238 rs587778670 Human genes 0.000 claims 1
- 102220315596 rs762200707 Human genes 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 253
- 229940024606 amino acid Drugs 0.000 description 121
- 102000004169 proteins and genes Human genes 0.000 description 92
- 150000007523 nucleic acids Chemical class 0.000 description 86
- 102000039446 nucleic acids Human genes 0.000 description 76
- 108020004707 nucleic acids Proteins 0.000 description 76
- 230000035772 mutation Effects 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 56
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 47
- 102000053602 DNA Human genes 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 230000006870 function Effects 0.000 description 26
- 239000013615 primer Substances 0.000 description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 22
- 239000000126 substance Substances 0.000 description 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 19
- 108060003951 Immunoglobulin Proteins 0.000 description 19
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 19
- 102000018358 immunoglobulin Human genes 0.000 description 19
- 108020004705 Codon Proteins 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 17
- 230000005714 functional activity Effects 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 229920002477 rna polymer Polymers 0.000 description 16
- 210000004754 hybrid cell Anatomy 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 241000894007 species Species 0.000 description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 13
- 239000012636 effector Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 12
- 102220542351 Endogenous retrovirus group K member 113 Pro protein_S28A_mutation Human genes 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 12
- 239000004473 Threonine Substances 0.000 description 12
- 102220553206 Transcription factor RelB_S28R_mutation Human genes 0.000 description 12
- 235000004279 alanine Nutrition 0.000 description 12
- 235000009582 asparagine Nutrition 0.000 description 12
- 229960001230 asparagine Drugs 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- 108091093037 Peptide nucleic acid Proteins 0.000 description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 235000013922 glutamic acid Nutrition 0.000 description 10
- 239000004220 glutamic acid Substances 0.000 description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000004474 valine Substances 0.000 description 10
- 101150117115 V gene Proteins 0.000 description 9
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 9
- 230000009824 affinity maturation Effects 0.000 description 9
- 235000003704 aspartic acid Nutrition 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
- 229960000310 isoleucine Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 108010087819 Fc receptors Proteins 0.000 description 8
- 102000009109 Fc receptors Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002823 phage display Methods 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102220250470 rs774802052 Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 102220364140 c.55A>G Human genes 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102220238245 rs1555952639 Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102220491789 High mobility group protein B1_S53A_mutation Human genes 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102220510697 APC membrane recruitment protein 1_T28A_mutation Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 101001130157 Dioclea sclerocarpa Lectin alpha chain Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102220491158 SET domain-containing protein 9_S76T_mutation Human genes 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102220580463 Thioredoxin domain-containing protein 11_Y32A_mutation Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012707 chemical precursor Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 102220554166 APC membrane recruitment protein 1_D50A_mutation Human genes 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 102220500580 Deleted in malignant brain tumors 1 protein_S52W_mutation Human genes 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 102220573074 Endonuclease V_Y91A_mutation Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102220529131 Eukaryotic translation initiation factor 2 subunit 1_S53P_mutation Human genes 0.000 description 3
- 108010008177 Fd immunoglobulins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 102220008235 rs199476326 Human genes 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010043648 Discoidin Domain Receptors Proteins 0.000 description 2
- 102000002706 Discoidin Domain Receptors Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 102000001753 Notch4 Receptor Human genes 0.000 description 2
- 108010029741 Notch4 Receptor Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 102220582305 Porphobilinogen deaminase_G24S_mutation Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108700003853 RON Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 102200050844 rs386833793 Human genes 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 241000284466 Antarctothoa delta Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000132092 Aster Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100074187 Caenorhabditis elegans lag-1 gene Proteins 0.000 description 1
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102220485758 Carbohydrate sulfotransferase 12_P52H_mutation Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100036462 Delta-like protein 1 Human genes 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102220597335 E3 ubiquitin-protein ligase TRIM21_P52A_mutation Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 101710102442 Erythropoietin receptor Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 101710142125 Granulocyte colony-stimulating factor receptor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- 102220588435 Keratin, type I cytoskeletal 18_S34A_mutation Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 101710189714 Major cell-binding factor Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 102220577739 Natural killer cell receptor 2B4_T76K_mutation Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102220596832 Non-structural maintenance of chromosomes element 1 homolog_E96A_mutation Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 1
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 108700037966 Protein jagged-1 Proteins 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000485664 Protortonia cacti Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100035712 Serrate RNA effector molecule homolog Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000003189 isokinetic effect Effects 0.000 description 1
- 238000002334 isothermal calorimetry Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000003537 radioprotector Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 210000005132 reproductive cell Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 102200033353 rs104893953 Human genes 0.000 description 1
- 102220065372 rs201453637 Human genes 0.000 description 1
- 102200082933 rs33968721 Human genes 0.000 description 1
- 102200001695 rs377767450 Human genes 0.000 description 1
- 102220279123 rs896054565 Human genes 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 244000195895 saibo Species 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005315 stained glass Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000032665 vasculature development Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Structural Engineering (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19876408P | 2008-11-07 | 2008-11-07 | |
| US61/198,764 | 2008-11-07 | ||
| US21120409P | 2009-03-25 | 2009-03-25 | |
| US61/211,204 | 2009-03-25 | ||
| PCT/US2009/063303 WO2010054010A1 (en) | 2008-11-07 | 2009-11-04 | Anti-dll4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157842A Division JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508017A true JP2012508017A (ja) | 2012-04-05 |
| JP2012508017A5 JP2012508017A5 (enExample) | 2013-01-24 |
Family
ID=41508157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9221902B2 (enExample) |
| EP (2) | EP2356146A1 (enExample) |
| JP (4) | JP2012508017A (enExample) |
| AU (4) | AU2009313551B2 (enExample) |
| CA (2) | CA2742968C (enExample) |
| DK (1) | DK2356270T3 (enExample) |
| WO (2) | WO2010054010A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537386A (ja) * | 2020-08-10 | 2023-08-31 | インテグラル・モレキュラー・インコーポレイテッド | 抗体ライブラリーを作製するための方法および組成物ならびにそれから単離された抗体 |
Families Citing this family (201)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053822A2 (en) * | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| MX2009012609A (es) | 2007-05-22 | 2009-12-07 | Amgen Inc | Composiciones y metodos para producir proteinas de fusion bioactivas. |
| CN101970493A (zh) | 2008-03-14 | 2011-02-09 | 百康有限公司 | 单克隆抗体及其方法 |
| EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| WO2010108153A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2010121370A1 (en) * | 2009-04-20 | 2010-10-28 | University Health Network | Prognostic gene expression signature for squamous cell carcinoma of the lung |
| US8685896B2 (en) | 2009-05-29 | 2014-04-01 | Morphosys Ag | Collection and methods for its use |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US10016620B2 (en) * | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
| WO2015200538A1 (en) * | 2014-06-24 | 2015-12-30 | Procept Biorobotics Corporation | Tissue sampling and cancer treatment methods and apparatus |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| ME02288B (me) | 2010-02-08 | 2016-02-20 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2806076A1 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| MX360946B (es) | 2010-09-22 | 2018-10-29 | Amgen Inc Star | Inmunoglobulinas portadoras y usos de las mismas. |
| CN103237809B (zh) | 2010-11-19 | 2016-09-07 | 莫佛塞斯公司 | 一个集合及其使用方法 |
| CA2834376A1 (en) * | 2011-04-28 | 2012-11-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing antibodies to nipah and hendra virus |
| ES2716013T3 (es) * | 2011-04-28 | 2019-06-07 | Univ Leland Stanford Junior | Identificación de polinucleótidos asociados a una muestra |
| HRP20200887T1 (hr) * | 2011-05-04 | 2020-09-04 | Omeros Corporation | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa |
| KR101629073B1 (ko) | 2011-06-15 | 2016-06-09 | 에프. 호프만-라 로슈 아게 | 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법 |
| CN103917650B (zh) | 2011-08-05 | 2017-10-24 | 瑞泽恩制药公司 | 人源化的通用轻链小鼠 |
| WO2013023251A1 (en) | 2011-08-18 | 2013-02-21 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
| JP6170496B2 (ja) | 2011-09-23 | 2017-07-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 |
| CN104053671A (zh) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | 治疗癌症的抗体和方法 |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| WO2013116296A1 (en) | 2012-01-31 | 2013-08-08 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| WO2013131074A1 (en) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| JP6181089B2 (ja) | 2012-03-08 | 2017-08-16 | ハロザイム インコーポレイテッド | 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法 |
| US10519245B2 (en) | 2012-06-21 | 2019-12-31 | Sorrento Therapeutics Inc. | Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| WO2014071018A1 (en) * | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| EP2917236A2 (en) * | 2012-11-06 | 2015-09-16 | MedImmune, LLC | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| WO2014085821A2 (en) * | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-met |
| ES2864326T3 (es) | 2012-12-05 | 2021-10-13 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a EPO |
| AU2014210475B2 (en) * | 2013-01-24 | 2017-03-02 | Abtlas Co., Ltd. | Protein combination-based Fv library, and preparation method therefor |
| DK2989239T4 (da) * | 2013-04-25 | 2025-04-07 | Sutro Biopharma Inc | Selektion af Fab-fragmenter ved anvendelse af ribosomfremvisningsteknologi |
| EP2989202B1 (en) | 2013-04-25 | 2019-04-10 | Sutro Biopharma, Inc. | The use of lambda-gam protein in ribosomal display technology |
| RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
| ES2837392T3 (es) * | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| BR112016020822A2 (pt) * | 2014-03-14 | 2017-10-03 | Genentech Inc | Métodos e composições para secreção de polipeptídeos heterólogos |
| WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| RU2761118C2 (ru) | 2014-04-03 | 2021-12-06 | АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. | Модифицированная j-цепь |
| AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CN106573154B (zh) | 2014-07-15 | 2021-06-15 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| MA40528A (fr) | 2014-08-29 | 2017-07-05 | Sorrento Therapeutics Inc | Anticorps thérapeutiques qui se lient à oprf et oprl |
| JP6709215B2 (ja) | 2014-10-27 | 2020-06-10 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 抗ｔｉｍ−３抗体 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| TW201625692A (zh) | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| WO2016090320A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| BR112017011914A2 (pt) | 2014-12-05 | 2018-02-27 | Memorial Sloan-Kettering Cancer Center | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? |
| WO2016114567A1 (ko) * | 2015-01-13 | 2016-07-21 | 이화여자대학교 산학협력단 | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 |
| TW201639891A (zh) * | 2015-03-10 | 2016-11-16 | 索倫多醫療公司 | 結合ｐｓｍａ之抗體治療劑 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016164669A2 (en) | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| JP6907124B2 (ja) | 2015-04-17 | 2021-07-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| EP3297663B1 (en) | 2015-05-18 | 2025-11-12 | Agensys, Inc. | Antibodies that bind to axl proteins |
| BR112017025496A2 (pt) | 2015-06-01 | 2018-08-07 | Medimmune, Llc | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas |
| US20180155411A1 (en) * | 2015-07-08 | 2018-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| EP3334842B1 (en) | 2015-08-12 | 2022-03-02 | Novartis AG | Methods of treating ophthalmic disorders |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| WO2017059387A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| CA3003468C (en) | 2015-11-10 | 2024-06-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2017096281A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| AU2016364891A1 (en) * | 2015-12-03 | 2018-06-07 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途 |
| CA3010223A1 (en) | 2016-01-08 | 2017-07-13 | Aimm Therapeutics B.V. | Therapeutic binding compounds |
| US20190015509A1 (en) | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
| US11505599B2 (en) | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| IL262207B1 (en) * | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3172367A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| MA45455A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
| WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| JP7274413B2 (ja) * | 2016-09-23 | 2023-05-16 | マレンゴ・セラピューティクス，インコーポレーテッド | ラムダ及びカッパ軽鎖を含む多重特異性抗体分子 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| AU2017359439B2 (en) | 2016-11-08 | 2024-11-28 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| TW201832778A (zh) * | 2016-11-10 | 2018-09-16 | 美商麥迪紐有限責任公司 | 對ａｓｃｔ２具有特異性的結合分子及其用途 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| FI3555132T3 (fi) * | 2016-12-19 | 2024-02-08 | Medimmune Ltd | Vasta-aineita LIF:iä vastaan ja niiden käyttöjä |
| KR20240023449A (ko) | 2017-02-08 | 2024-02-21 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| US11161905B2 (en) * | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
| US11976121B2 (en) | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
| IL272367B2 (en) | 2017-07-31 | 2025-08-01 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| JP7291700B2 (ja) | 2017-11-20 | 2023-06-15 | ナントバイオ，インコーポレイテッド | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| CN111727203B (zh) | 2017-12-19 | 2024-04-26 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| WO2019143884A1 (en) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Conserved hiv antibody clonotypes and methods of use |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JOP20200215A1 (ar) | 2018-03-05 | 2020-09-03 | Janssen Pharmaceutica Nv | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها |
| US10738125B2 (en) * | 2018-03-13 | 2020-08-11 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| AU2019249273A1 (en) | 2018-04-06 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
| EP3553081A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
| JP7332691B2 (ja) | 2018-07-08 | 2023-08-23 | スペシフィカ インコーポレイティド | 抗体の開発可能性が最大化された抗体ライブラリー |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| CA3110089A1 (en) | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
| JP7506607B2 (ja) * | 2018-12-28 | 2024-06-26 | 協和キリン株式会社 | ＴｆＲに結合するバイスペシフィック抗体 |
| KR102736548B1 (ko) * | 2019-01-31 | 2024-12-02 | 난트바이오 인코포레이티드 | Mrna 디스플레이 항체 라이브러리 및 방법 |
| BR112021017537A2 (pt) | 2019-03-05 | 2021-12-14 | Nkarta Inc | Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia |
| WO2020205775A1 (en) * | 2019-03-29 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (pd1) and uses thereof |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| WO2020247883A2 (en) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| US12448462B2 (en) | 2019-06-14 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 |
| US20220275095A1 (en) * | 2019-07-02 | 2022-09-01 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| KR20220034857A (ko) * | 2019-07-16 | 2022-03-18 | 사노피 | 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 |
| WO2021061829A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| JP2022548783A (ja) * | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| CN116063517A (zh) * | 2019-10-24 | 2023-05-05 | 普罗米修斯生物科学公司 | Tnf样配体1a(tl1a)的人源化抗体及其用途 |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| WO2021222316A2 (en) | 2020-04-27 | 2021-11-04 | Twist Bioscience Corporation | Variant nucleic acid libraries for coronavirus |
| CA3177024A1 (en) | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
| US20230203134A1 (en) * | 2020-05-20 | 2023-06-29 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| CA3184752A1 (en) * | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| CA3183565A1 (en) * | 2020-06-30 | 2022-01-06 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| KR20230118134A (ko) * | 2020-12-04 | 2023-08-10 | 이퀼리엄 아이엔씨 | CD6 high 세포 선택적 표적화 및 T eff 세포의 활성감소 방법 |
| US20240228588A1 (en) * | 2021-01-11 | 2024-07-11 | Adimab, Llc | Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2022192661A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Sars-cov-2 neutralizing antibodies and uses thereof |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| IL309422A (en) | 2021-06-17 | 2024-02-01 | Atreca Inc | Antibodies against CSP |
| MX2024000675A (es) * | 2021-07-12 | 2024-02-07 | Nkarta Inc | Composiciones y metodos de inmunoterapia celular dirigida a bcma. |
| AU2022313322A1 (en) * | 2021-07-23 | 2024-02-01 | The Trustees Of Columbia University In The City Of New York | Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use |
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| KR20240049342A (ko) * | 2021-08-27 | 2024-04-16 | 얀센 바이오테크 인코포레이티드 | 항-psma 항체 및 이의 용도 |
| KR20240053607A (ko) * | 2021-08-27 | 2024-04-24 | 얀센 바이오테크 인코포레이티드 | 항-psma 방사성 접합체 및 이의 용도 |
| CN118234750A (zh) * | 2021-09-02 | 2024-06-21 | 纪念斯隆-凯特琳癌症中心 | 抗cd33抗体和其用途 |
| JP2024535740A (ja) * | 2021-09-02 | 2024-10-02 | メモリアル スローン ケタリング キャンサー センター | Ｃｄ３３を標的とする抗原認識受容体及びその使用 |
| WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
| US20230265217A1 (en) * | 2021-10-27 | 2023-08-24 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| US20250188189A1 (en) * | 2022-03-04 | 2025-06-12 | Coagulant Therapeutics Corporation | Human antibodies against activated protein c and uses thereof |
| JP2025534161A (ja) * | 2022-10-04 | 2025-10-14 | ミンク セラピューティクス， インコーポレイテッド | 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用 |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| WO2025010375A2 (en) * | 2023-07-03 | 2025-01-09 | Uct Bioscience Co., Ltd. | Anti-grp78 antibodies and their uses |
| WO2025015320A2 (en) * | 2023-07-12 | 2025-01-16 | Phenomic Ai | Anti-cthrc1 t cell engagers and methods of using the same |
| TW202525855A (zh) * | 2023-08-31 | 2025-07-01 | 美商艾克塞里克斯公司 | Ｉｌｔ２結合劑及其用途 |
| US20250121007A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025184137A1 (en) * | 2024-02-27 | 2025-09-04 | Adimab, Llc | Influenza antibodies and methods of use thereof |
| CN117986346B (zh) * | 2024-04-07 | 2024-07-26 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
| CN120399078A (zh) * | 2025-05-08 | 2025-08-01 | 上海天泽云泰生物医药有限公司 | 靶向cd117的纳米抗体及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143689A2 (en) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| WO2008042236A2 (en) * | 2006-09-29 | 2008-04-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| WO2008060705A2 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| WO2008076379A2 (en) * | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
| WO2008139202A1 (en) * | 2007-05-15 | 2008-11-20 | Smart Targeting Limited | Neutralizing monoclonal antibody against human dll4 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
| DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| ES2275304T3 (es) | 1997-04-04 | 2007-06-01 | Millennium Pharmaceuticals, Inc. | Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| JP4171528B2 (ja) | 1997-05-14 | 2008-10-22 | 旭化成株式会社 | 新規な分化抑制剤 |
| JP2002523018A (ja) | 1998-07-27 | 2002-07-30 | アムジエン・インコーポレーテツド | デルタ関連ポリペプチド |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| DK1292335T3 (da) | 2000-06-23 | 2007-09-17 | Bayer Schering Pharma Ag | Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II) |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| JP2005503792A (ja) | 2001-08-22 | 2005-02-10 | ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ | ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| AU2003248548B2 (en) * | 2002-05-20 | 2010-03-11 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20120202710A1 (en) * | 2003-09-09 | 2012-08-09 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| AU2006210660B2 (en) | 2005-02-01 | 2011-12-01 | Morphosys Ag | Libraries and methods for isolating antibodies |
| JP2009515516A (ja) | 2005-11-14 | 2009-04-16 | バイオレン・インク | 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化 |
| JP5489465B2 (ja) | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| WO2007137616A1 (en) | 2006-05-30 | 2007-12-06 | Millegen | Highly diversified antibody libraries |
| MY150092A (en) | 2006-08-07 | 2013-11-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
| EP2125013A4 (en) | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | DLL4 SIGNALING INHIBITOR AND ITS USES |
| EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
-
2009
- 2009-11-04 EP EP09748672A patent/EP2356146A1/en not_active Withdrawn
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/en not_active Ceased
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/en active Active
- 2009-11-04 US US13/128,236 patent/US9403904B2/en not_active Expired - Fee Related
- 2009-11-04 CA CA2742968A patent/CA2742968C/en not_active Expired - Fee Related
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 CA CA2742969A patent/CA2742969A1/en not_active Abandoned
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/en not_active Ceased
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143689A2 (en) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| WO2008060705A2 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| WO2008042236A2 (en) * | 2006-09-29 | 2008-04-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| WO2008076379A2 (en) * | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
| WO2008139202A1 (en) * | 2007-05-15 | 2008-11-20 | Smart Targeting Limited | Neutralizing monoclonal antibody against human dll4 |
Non-Patent Citations (1)
| Title |
|---|
| RIDGWAY, J. ET AL.: ""INHIBITION OF DLL4 SIGNALLING INHIBITS TUMOUR GROWTH BY DEREGULATING ANGIOGENESIS."", NATURE, vol. 444, no. 7122, JPN5012002355, 21 December 2006 (2006-12-21), pages 1083 - 1087, XP002489428, ISSN: 0002794286, DOI: 10.1038/nature05313 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537386A (ja) * | 2020-08-10 | 2023-08-31 | インテグラル・モレキュラー・インコーポレイテッド | 抗体ライブラリーを作製するための方法および組成物ならびにそれから単離された抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016040246A (ja) | 2016-03-24 |
| AU2016204719A1 (en) | 2016-07-28 |
| CA2742969A1 (en) | 2010-05-14 |
| US20160194627A1 (en) | 2016-07-07 |
| AU2009313551B2 (en) | 2015-12-17 |
| US20110318339A1 (en) | 2011-12-29 |
| AU2009313560A1 (en) | 2010-05-14 |
| EP2356270B1 (en) | 2016-08-24 |
| US20200399359A1 (en) | 2020-12-24 |
| JP2012508016A (ja) | 2012-04-05 |
| AU2009313551A1 (en) | 2010-05-14 |
| WO2010054010A1 (en) | 2010-05-14 |
| AU2018201622A1 (en) | 2018-03-29 |
| CA2742968C (en) | 2020-06-09 |
| US9221902B2 (en) | 2015-12-29 |
| AU2009313560B2 (en) | 2016-04-14 |
| JP5882058B2 (ja) | 2016-03-09 |
| CA2742968A1 (en) | 2010-05-14 |
| JP2016127850A (ja) | 2016-07-14 |
| DK2356270T3 (da) | 2016-12-12 |
| US10774138B2 (en) | 2020-09-15 |
| US9403904B2 (en) | 2016-08-02 |
| US20120058906A1 (en) | 2012-03-08 |
| WO2010054007A1 (en) | 2010-05-14 |
| EP2356270A1 (en) | 2011-08-17 |
| EP2356146A1 (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508017A (ja) | 抗ｄｌｌ４抗体及びその使用 | |
| JP6007420B2 (ja) | 親和性成熟に基づく抗体最適化方法 | |
| CN105814074B (zh) | 具有超长互补决定区的人源化抗体 | |
| US20110189183A1 (en) | Antibodies against candida, collections thereof and methods of use | |
| JP2018095645A (ja) | ヒト化抗体 | |
| US20060018911A1 (en) | Design of therapeutics and therapeutics | |
| JP2001509817A (ja) | 抗ｖｅｇｆ抗体 | |
| CN107428838A (zh) | 结合tfpi的新型抗体以及包含所述抗体的组合物 | |
| US20250313621A1 (en) | Anti-par2 antibodies | |
| JP6903083B2 (ja) | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140418 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140714 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140722 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150410 |